Results 191 to 200 of about 2,997 (217)

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

Dalton Transactions, 2017
A comparison of four bifunctional chelating agents showed superior behaviour of a new NOTA derivative for 64Cu labelling of antibody fragments.
Moreau, M., Poty, Sophie, Vrigneaud, J-M, Walker, P., Guillemin, M., Raguin, O., Oudot, A., Bernhard, C., Gozé, C., Boschetti, F., Collin, B., Brunotte, F., Denat, Franck   +12 more
openaire   +2 more sources

ImmunoPET Demonstrates that Co-Targeting GD2 and B7-H3 with Bispecific Antibodies Enhances Tumor Selectivity in Preclinical Melanoma Models.

Bioconjugate chemistry
Disialoganglioside 2 (GD2) is overexpressed in multiple cancers, such as melanoma and neuroblastoma, but also in peripheral nerves. To improve current GD2-targeting approaches, next-generation heterodimeric bispecific human IgG antibodies were created ...
Z. Rosenkrans, Amy K. Erbe, Nathan B Clemons, Arika S. Feils, Y. Medina-Guevara, J. Jeffery, Todd E. Barnhart, Jonathan W. Engle, Paul M. Sondel, Reinier Hernandez   +9 more
semanticscholar   +1 more source

Predictive imaging of the immunotherapy and radioimmunotherapy response by immunoPET via a new target (CD103) and innovative protein formats in preclinical NSCLC.

Journal of Clinical Oncology
2559 Background: Immune checkpoint immunotherapies (ICI) have transformed cancer treatment, but patients have varied responses and potential risks of autoimmune disease. To improve ICI, we need to identify biomarkers to select responding patients
Léa Zimmermann, Céline Chevaleyre, Dimitri Kereselidze, S. Dubois, Corinne Tanchot, E. Tartour, Bernard Maillère, H. Nozach, C. Truillet   +8 more
semanticscholar   +1 more source

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood
Evaluation of multiple myeloma disease burden and response to therapy are currently suboptimal. For instance, ~30% of myeloma lytic bone lesions are not detected by standard FDG PET imaging. This limits treatment planning and evaluation of residual
O. Landgren, R. Kuker, Ryan Reddy, Alanna M. Vossen, Jayashree Motwani, Benjamin H Goldenson, B. Diamond, Abhishek Pandey, James Hoffman, D. Coffey, Marcella Kaddoura, Mike Georgiou, Brian Walker, Rabia Bukhari, Caterine Diaz, Stephanie Mompoint, Sindy Gutierrez, Kellye Koubek, Stephanie Fernandes, Michelle Armogan, D. Kazandjian, Gary A. Ulaner   +21 more
semanticscholar   +1 more source

B7-H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer.

Molecular Pharmaceutics
B7-H4 is an inhibitory immune checkpoint molecule that is upregulated in various cancers and correlates with advanced tumor stages and poor clinical outcomes.
Manoj Kumar, Shashi B Singh, Iryna Vasyliv, F. Habte, Mausam Kalita, Israt S. Alam, Abhishek Koladiya, S. Dai, Michelle L. James, Jianghong Rao, N. Beziere, Heike E Daldrup-Link   +11 more
semanticscholar   +1 more source

Preclinical ImmunoPET Imaging of Thyroid-Stimulating Hormone Receptor Expression in Thyroid Cancer using [64Cu]Cu-NOTA-TSHR-Ab.

Molecular Pharmaceutics
Advanced thyroid cancers are aggressive and often refractory to the current standard of care. The thyroid-stimulating hormone receptor (TSHR) is highly expressed in thyroid cancers and rarely expressed outside the thyroid, making it a viable target for ...
Wenhui Fu, Ephraim E Parent, J. Gleba, Joshua A Knight, Otto Muzik, John A. Copland, Hancheng Cai   +6 more
semanticscholar   +1 more source

89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors

Molecular Cancer Therapeutics
Abstract Epithelial membrane protein-2 (EMP2) is upregulated in a number of tumors and therefore remains a promising target for mAb-based therapy. In the current study, image-guided therapy for an anti-EMP2 mAb was evaluated by PET in both syngeneic and immunodeficient cancer models expressing different levels of EMP2 to enable a ...
Ann M. Chan, Tove Olafsen, Jessica Tsui, Felix B. Salazar, Brian Aguirre, Kirstin A. Zettlitz, Michael Condro, Anna M. Wu, Jonathan Braun, Lynn K. Gordon, Negin Ashki, Julian Whitelegge, Shili Xu, Oluwatayo Ikotun, Jason Thanh Lee, Madhuri Wadehra   +15 more
openaire   +2 more sources

Nanobody-Based ImmunoPET for Hepatocellular Carcinoma

International Journal of Radiation Oncology*Biology*Physics, 2023
S. Fayn, A.P. King, N.T. Gutsche, Z. Duan, J. Buffington, C.P. Olkowski, Y. Fu, J. Hong, D. Sail, K.E. Baidoo, R.E. Swenson, R.W. Cheloha, M. Ho, P. Choyke, F.E. Escorcia   +14 more
openaire   +1 more source

Non-invasive imaging of CLDN18.2 expression in gastric adenocarcinoma: synthesis, preclinical evaluation, and preliminary clinical study of a novel [89Zr]Zr-DFO-NY005 ImmunoPET tracer.

International Journal of Radiation Oncology, Biology, Physics
BACKGROUND Claudin 18.2 is predominantly expressed in gastric mucosa and becomes exposed and accessible during malignant transformation. Its highly restricted expression pattern and function in gastric cancer make CLDN18.2 a promising target for the ...
Jialiang Wang, Kequan Lou, Liping Chen, Yu Zhang, Huihui He, Qiao-ling Xu, Najing Wu, Quanpeng Wang, Qingbo Li, Yanjuan Wang, Haitian Fu, Chunjing Yu, Yong Mao   +12 more
semanticscholar   +1 more source

Preclinical development of CD133 targeted immunoPET probes

Nuclear Medicine and Biology, 2022
Kevin Wyszatko, Luis Rafael Silva, Teesha Komal, Luke Yongkyu Kwon, Manuela Ventura, Sheila Singh, John Valliant, Saman Sadeghi   +7 more
openaire   +1 more source